

## ***Alberta Drug Benefit List (ADBL) interim update now available online***

Please be advised that the **November 1, 2023**, update to the *Alberta Drug Benefit List (ADBL)* has been posted online at [ab.bluecross.ca/dbl/publications.php](http://ab.bluecross.ca/dbl/publications.php).

Please refer to the **November 1, 2023**, update for complete listings of products available by special authorization, step therapy/special authorization, changes to criteria for coverage, restricted benefits, added products, new established interchangeable groupings, least cost alternative price changes, products with a price change, discontinued products and delisted products.

Please note that the online *interactive Drug Benefit List (iDBL)* at [ab.bluecross.ca/dbl/idbl\\_main1.php](http://ab.bluecross.ca/dbl/idbl_main1.php) is a near real-time application, and as such, contains the most up-to-date information.

### **Temporary benefits added to the ADBL**

Due to the unavailability of Acetylcysteine 20% Inhalation Solution (DIN 02243098) manufactured by Sandoz Canada Inc., **Acetylcysteine 20% Inhalation Solution USP (DIN 02459906)** manufactured by Hikma Pharmaceuticals will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **September 29, 2023**.

As of **September 29, 2023**, all claims for Acetylcysteine 20% Inhalation Solution USP (DIN 02459906) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php).

### **Removal of temporary benefit from the ADBL**

Due to the shortage of Diphenhydramine HCl 50 mg/mL Injection (DIN 00596612) manufactured by Sandoz Canada Inc., Diphenhydramine Hydrochloride 50 mg/mL Injection (DIN 02369567) manufactured by Fresenius Kabi Canada was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross® has confirmed that the shortage for Diphenhydramine HCl 50 mg/mL Injection (DIN 00596612) has been resolved.

**Diphenhydramine Hydrochloride 50 mg/mL Injection (DIN 02369567)** will no longer be considered a temporary benefit for the *ADBL* **after October 31, 2023**. The above grouping was removed from the Critical Supply Product List **October 3, 2023**.

Due to the shortage of Zomig Rapimelt 2.5 mg Oral Dispersible Tablet (DIN 02243045) manufactured by Xediton Pharmaceuticals Inc., Teva-Zolmitriptan OD 2.5 mg Oral Dispersible Tablet (DIN 02342545) manufactured by Teva Canada Limited was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross has confirmed that the shortage for Zomig Rapimelt 2.5 mg Oral Dispersible Tablet (DIN 02243045) has been resolved.

**Teva-Zolmitriptan OD 2.5 mg Oral Dispersible Tablet (DIN 02342545)** will no longer be considered a temporary benefit for the *ADBL* **after November 21, 2023**. The above product was removed from the Critical Supply Product List **October 20, 2023**.

*continued next page*

# PHARMACY BENEFACT

continued from previous page

## Product supply shortages addressed for ADBL

Alberta Blue Cross has confirmed that the shortage for Sandoz Sitagliptin-Metformin 50 mg/500 mg Tablet (DIN 02503956) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **November 13, 2023**. The following grouping was removed from the Critical Supply Product List **October 13, 2023**.

### SITAGLIPTIN / METFORMIN HCL

#### 50 MG / 500 MG TABLET

00002503956	SANDOZ SITAGLIPTIN-METFORMIN	SDZ	\$ 0.8893
00002333856	JANUMET	MFC	\$ 1.7465

Alberta Blue Cross has confirmed that the shortage for Ketorolac 0.5% Ophthalmic Solution (DIN 02245821) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **November 17, 2023**. The following grouping was removed from the Critical Supply Product List **October 18, 2023**.

### KETOROLAC TROMETHAMINE

#### 0.5% OPHTHALMIC SOLUTION

00002245821	KETOROLAC	AAP	\$ 2.8997
00001968300	ACULAR	ABV	\$ 3.6490

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

